Latest

Pharma Andrew Joseph

STAT Plus: As targeted radiation field heats up, AstraZeneca to acquire Fusion Pharmaceuticals in $2 billion deal

Politics Sarah Owermohle

Supreme Court questions restricting government efforts to limit Covid-19 misinformation

Biotech Jason Mast

STAT Plus: FDA approves first gene therapy for fatal neuron disease in children

Health Associated Press

EPA bans asbestos, a deadly carcinogen still in use decades after partial ban

The Readout Meghana Keshavan

STAT Plus: Contineum Therapeutics files for IPO

Adam's Take Adam Feuerstein

STAT Plus: I was wrong about Geron’s blood cancer drug. Now, is it a takeover target?

Off the Charts Jennifer Adaeze Okwerekwu

The harms of adverse childhood experiences are well-known. But positive experiences can affect future health, too

Health tech Mohana Ravindranath

STAT Plus: As AI marches into medicine, investors eye security, privacy startups

Exclusive Bob Herman

STAT Plus: As Humira biosimilars take over the market, CVS has created a new ploy: the drug ‘rebate credit’

Biotech Catherine Carlock — Boston Globe

STAT Plus: The Boston area built a ton of lab space. Now many of those buildings are opening empty

Health Katherine MacPhail

The latest twist in John Green’s anti-tuberculosis story: working with governments

Biotech Damian Garde

STAT Plus: FDA advisers back CAR-T therapies in blood cancer, despite safety concerns

In the Lab Theresa Gaffney

Q&A: Is it time for scientists to rethink how they study sex in research?

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

The Readout Meghana Keshavan

STAT Plus: What happens when an approved drug doesn’t work?

First Opinion Thiago Arzua

Lessons for scientists from the All of Us Research Program backlash

Pharma Allison DeAngelis

STAT Plus: Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

In the Lab Nicholas StFleur

What the brains of songbirds can teach us about human stuttering

Health Isabella Cueto

STAT Plus: Inside a push to create an NIH office for post-infection chronic illness

The Readout LOUD Damian Garde, Allison DeAngelis, and Adam Feuerstein

Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard

Biotech Adam Feuerstein

STAT Plus: Madrigal wins first U.S. approval for drug to treat liver disease MASH

Politics Sarah Owermohle

STAT Plus: Senators press HHS secretary on Change HealthCare cyberattack fallout

Health Helen Branswell

Study: Gilead antiviral drug shows promise as a treatment for Ebola Sudan

Health tech Lizzy Lawrence

STAT Plus: EPA restricts cancer-causing chemical used to sterilize medical devices

Pharma Ed Silverman

STAT Plus: Virtual Event: March of the Biosimilars

The Readout Damian Garde

STAT Plus: Is CAR-T safe for early-stage patients?

Biotech Andrew Joseph

STAT Plus: Vertex hits speed bump in getting CRISPR sickle cell therapy covered in U.K.

Pharma Andrew Joseph

STAT Plus: AstraZeneca picks up rare disease-focused Amolyt Pharma in $1 billion deal

First Opinion Jonathan Slotkin and David Vawdrey

Prescription for resilience: Health care needs financial sector-inspired regulation